Global Medicines Regulators Lay Down Principles for Safe AI Across the Drug Lifecycle
International regulators are moving to define baseline principles for AI use across the medicines lifecycle, from discovery through post-market activities. The guidance is important because it signals that oversight is broadening beyond medical devices toward the full pharmaceutical value chain.
The release of global regulatory principles for safe AI across the medicines lifecycle is a meaningful development because it widens the frame of healthcare AI governance. Much of the regulatory focus to date has centered on clinical software and software as a medical device. By contrast, this effort recognizes that AI now influences decisions in discovery, development, manufacturing, pharmacovigilance, and regulatory submissions themselves.
That matters for two reasons. First, AI-generated outputs in pharma are increasingly upstream of major capital allocation and patient safety decisions, even when they are not patient-facing products. Second, companies have been building AI programs faster than regulators have articulated consistent expectations for transparency, data quality, accountability, and change management. Principles-based alignment helps close that gap without freezing innovation.
The likely impact will be less about immediate enforcement and more about operational normalization. Companies will need stronger documentation of model provenance, intended use, human oversight, and performance monitoring. In practice, this pushes AI in pharma toward quality systems thinking: if a model influences regulated decisions, it will need a governance framework that resembles other controlled processes.
For the industry, the message is clear: AI in medicines is no longer treated as a peripheral digital tool. Regulators increasingly view it as infrastructure that must be managed across the product lifecycle, which raises the bar for both internal compliance and vendor accountability.